OBJECTIVES: Diabetes mellitus (DM) represents a challenging problem to healthcare systems globally as it requires a high level of expenditure. In Algeria, nearly US$264 million was spent on DM in 2010; this is expected to rise to US$461 million by 2030. The aim of this study was to collect 2011 direct medical costs of the management and treatment of DM-related complications from the Algerian Social Insurance perspective. METHODS: A structured literature search was conducted to search for the published costs of interest but no relevant publications were identified. Consequently, IMS collected the required costs from official sources identified using its local resources. Six groups of costs were created based mainly on type of complications: management costs, cardiovascular complications, renal complications, acute events, eye-disease and neuropathy/foot ulcers which were presented as first-year costs and costs in subsequent years following an event in 2011
OBJECTIVES: Health care systems in many countries are facing a significant financial burden due to the costs incurred by treating Diabetes mellitus (DM). In Brazil, expenditure on DM care in 2010 was estimated at US$4.3 million and is expected to rise to nearly US$7.2 million by 2030. This study aims to collect up-to-date direct medical costs of managing and treating DM-related complications from the Brazilian health care system perspective. METHODS: Most costs were obtained from the Brazilian Ministry of Health and published studies identified through a structured literature search. Pre-2011 costs were inflated using the Consumer Price Index. Costs were categorised in six groups: management costs, cardiovascular complications, renal complications, acute events, eye-disease and neuropathy/foot ulcers. Costs were expressed in 2011 US-dollars in accordance with the average annual exchange rate (1 US$ϭ1.669 BRL) and were reported as per event costs in the first-year of the event and in subsequent years following the event. RESULTS:
First-year haemodialysis and renal transplantation costs were the highest costs observed overall at US$14,855 and US$14,051, respectively. The highest first-year cost of treating cardiovascular complications was that for myocardial infarction (US$4752). Other first-year costs of treating cardiovascular complications were: congestive heart failure (US$2,852), stroke (US$1812) and angina (US$532). The cost of an amputation procedure was US$3771 without the cost of prosthesis (US$1584). The cost of a laser eye operation was US$2064 and the cataract operation cost was US$507. CONCLUSIONS: DM-related complications impose significant costs on the Brazilian health care budget which highlights the importance of conducting economic evaluations to assess the impact of DM-related treatments on treatment costs and health outcomes. Costs from this study can be used to conduct such economic evaluations which provide valuable information to decision makers in the assessment of DM-related treatments.
PDB49 COST BENEFIT ANALYSIS OF A DIABETES PREVENTION PROGRAM IN RURAL KENYA
Kangethe AW, Franic D, Corso PS, Southwood R University of Georgia, Athens, GA, USA OBJECTIVES: In Kenya, diabetes prevalence is comparable to Western countries. In Sub-Saharan countries, the emphasis must be on prevention because the Western model of emphasizing treatment is unaffordable and unachievable. This study is a cost benefit analysis (CBA) of a diabetes prevention program in rural Kenya. METHODS: Convenience sample of adult residents from a rural county in Kenya (Kiambu) were randomized to one of two WTP techniques, Structured Haggling (SH) and Payment Card (PC). Program benefits (WTP) were collected via face-to-face interviews using the ex-ante approach. Program costs were estimated based on World Health Organization program cost estimation guidelines for low income countries in Africa, and program costs tabulated in the literature (eg Haddix et al 2006) , supplemented expert opinion: diabetes educators at the Kenya Diabetes Management and Information Centre. RESULTS: WTP data was collected from 158 rural residents (70% male, 2.5% diabetic,11% own a vehicle and mean monthly expenditures of Ksh10,933 (US2011$ 127.12). Mean annual WTP for the prevention program was Ksh628.75 (US2011$7.30) for PC and Ksh683.97 (US2011$7.95) for SH per respondent per year, pϭ0.516. Mean annual cost for providing the program to rural residents (assuming 100 clients/week) was Ksh1,228 (US2011$14). Therefore, program cost exceeded the benefit resulting in a negative net social benefit (NSB). CONCLUSIONS: Based on WTP (benefit) data, residents valued the diabetes prevention program in rural Kenya. From a societal perspective, however, the costs for implementing the program outweighed the benefits. The evaluated program is a stand-alone project. Policy makers may consider a number of options that can reduce the operating costs of the program including, implementation of the program as part of established diabetes clinics, or administering the services to already gathered groups such as at religious functions: such an approach may result in a positive NSB.
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LONG-TERM CLINICAL AND ECONOMIC BENEFIT ASSOCIATED WITH LIRAGLUTIDE VERSUS SITAGLIPTIN THERAPY WHEN ADDED TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES: A CORE DIABETES MODEL STUDY
Lee WC 1 , Samyshkin Y 2 , Langer J 3 , Palmer JL 4 1 IMS Health Consulting Group, Alexandria, VA, USA, 2 IMS Health Consulting Group, London, UK, 3 Novo Nordisk, Inc., Princeton, NJ, USA, 4 IMS Health Consulting Group, Allschwil, Switzerland OBJECTIVES: A recent randomized, open-label, parallel group trial showed that liraglutide is superior to sitagliptin for reduction of HbA1c. Although these findings support the use of liraglutide as an effective GLP-1 agent to add to metformin, the value of liraglutide needs to be quantified in the framework of a cost-effectiveness (CE) analysis in a US setting. This current study sets out to assess the long-term CE outcomes of liraglutide vs. sitagliptin based on treatment effects data from the 52-week trial. METHODS: The IMS CORE Diabetes Model, a non-product-specific, validated computer simulation model that projects the long-term outcomes related to interventions for type 2 diabetes, is used for simulation over 35 years. Patients were simulated on one of the 3 treatment options: liraglutide 1.2 mg daily, 1.8 mg daily, or sitagliptin 100 mg daily, each used as add-on therapy to metformin. Incremental cost-effectiveness ratios (ICER) were generated for liraglutide 1.2 mg versus sitagliptin and liraglutide 1.8 mg versus sitagliptin. Transition probabilities, health state utility values and complication costs were obtained from published sources. All outcomes were discounted at 3% per annum, and the analysis was conducted from the perspective of a third-party payer in the US. Sensitivity analyses were performed to test robustness of the base case scenario. RESULTS: For liraglutide 1.8 mg versus sitagliptin, the ICER was $37,234 per QALY gained, while for liraglutide 1.2 mg versus sitagliptin, the ICER was $25,742 per QALY gained. In all sensitivity analyses including setting the HbA1c reduction to its 95% lower limit, the ICERs remained below USD 50,000/QALY, a commonly accepted threshold in the United States, except for the shortest time horizon of 10 years. CONCLUSIONS: The availability of liraglutide 1.2 mg and 1.8 mg with improved efficacy profiles over sitagliptin could improve patient care, while being cost-effective treatment options as add-on to metformin.
